![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, May 04, 2023 10:55:11 PM
Hard work in the laboratory
What did they share with SAGA that they will pay ENZC 250 Million dollars?
Don't know however it must have been a hell of a sale
Who are these pipe investors bringing up the rear?
Don't know
Are we getting shares of SAGA Scientific Holdings Corp.?
This is an interesting question because under a "normal" SPAC a private/public (the target) company gets bought out/merged with the SPAC and shares are distributed with the target getting the majority shares.
In our situation we are selling two subsidiaries for $250,000,000 while the Parent company remains intact.
This creates uncertainty as to if we get shares.
IMO I think we get some because for one our management team is running the new company (which is normal under SPAC) and some of our technology that wasn't part of the original license agreements is being used in the new company.
Formation of Two New Wholly-Owned Subsidiaries
Pursuant to the terms of the Business Combination Agreement, on November 24, 2020, the Company formed two new Texas corporations as wholly-owned subsidiaries for the purpose of licensing certain patented technologies: Biogenysis, Inc. and Virogentics, Inc.
Two Patent License Agreements
On November 30, 2020, Biogenysis, Inc., a wholly-owned subsidiary of Enzolytics, Inc., entered into a Patent License Agreement with Bioclonetics in order to license the U.S. Provisional Patent Application No. 63/078,482, filed September 15, 2020, entitled NOVEL HIV-BINDINGPEPTIDES for treating, preventing and reducing the risks of HIV, including all patents issuing therefrom and any foreign counterparts thereof.
Also on November 30, 2020, Virogentics, Inc., a wholly-owned subsidiary of Enzolytics, Inc., entered into a Patent License Agreement with the Zhabilov Trust in order to license the U.S. Patent No. 7,479538, entitled Irreversibly - Inactivated pepsinogen fragment and Pharmaceutical composition the same for detecting preventing and treating HIV; U.S. Patent No. 8,066982, Irreversibly - Inactivated pepsinogen fragment and Pharmaceutical composition compressing the same for detecting preventing and treating HIV, including all patents issuing therefrom and any foreign counterparts thereof.
What will the dividend be?
Don't know
When will we get an Africa ITV-1 therapeutic update?
Soon I hope
Enzolytics is a time bomb with a LIT fuse with many warheads attached going in different directions that is about to BLOW time after time.
Watch out!!!
![Bullish](/static/images/ih2-bull.png)
Recent ENZC News
- Small Cap Recipient of Military Drone Technology • InvestorsHub NewsWire • 11/20/2023 01:14:45 PM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM